One connector, four scholarly indexes, real DOIs and legal free PDFs. Works in Claude and ChatGPT.
Paste it into Claude or ChatGPT as a custom connector. 3-day free trial.
Chad Bousman, James Michael Stevenson, Laura B. Ramsey, Katrin Sangkuhl, James Kevin Hicks, Jeffrey Robert Strawn, Ajeet Singh, Gualberto Ruaño, Daniel J. Müller, Evangelia Eirini Tsermpini and 8 more
Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake inhibitors (SSRIs; i.e., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline), serotonin and norepinephrine reuptake inhibitors (i.e., desvenlafaxine, duloxetine, levomilnacipran, milnacipran, and venlafaxine), and serotonin modulators with SSRI-like properties (i.e., vilazodone and vortioxetine) are primary pharmacologic treatments for major depressive and anxiety disorders. Genetic variation in CYP2D6, CYP2C19, and CYP2B6 influences the metabolism of many of these antidepressants, which may potentially affect dosing, efficacy, and tolerability. In addition, the pharmacodynamic genes SLC6A4 (serotonin transporter) and HTR2A (serotonin-2A receptor) have been examined in relation to efficacy and side effect profiles of these drugs. This guideline updates and expands the 2015 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and SSRI dosing and summarizes the impact of CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes on antidepressant dosing, efficacy, and tolerability. We provide recommendations for using CYP2D6, CYP2C19, and CYP2B6 genotype results to help inform prescribing these antidepressants and describe the existing data for SLC6A4 and HTR2A, which do not support their clinical use in antidepressant prescribing.
Formatted from the source metadata, not typed by hand. For a whole reference list, use the citation generator or ask your assistant through Find Research.
Bousman, C., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A., Ruaño, G., Müller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, J. S., Gaedigk, A., Scott, S. A., Klein, T. E., Caudle, K. E., & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51–68. https://doi.org/10.1002/cpt.2903
Bousman, Chad, et al. "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants." Clinical Pharmacology & Therapeutics, vol. 114, no. 1, 2023, pp. 51–68, https://doi.org/10.1002/cpt.2903.
Bousman, Chad, James Michael Stevenson, Laura B. Ramsey, Katrin Sangkuhl, James Kevin Hicks, Jeffrey Robert Strawn, Ajeet Singh, et al. "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants." Clinical Pharmacology & Therapeutics 114, no. 1 (2023): 51–68. https://doi.org/10.1002/cpt.2903.
Bousman C., Stevenson J. M., Ramsey L. B. [и др.] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants // Clinical Pharmacology & Therapeutics. — 2023. — Vol. 114, № 1. — P. 51–68. — URL: https://doi.org/10.1002/cpt.2903
@article{bousman2023clinical,
title = {{Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants}},
author = {Chad Bousman and James Michael Stevenson and Laura B. Ramsey and Katrin Sangkuhl and James Kevin Hicks and Jeffrey Robert Strawn and Ajeet Singh and Gualberto Ruaño and Daniel J. Müller and Evangelia Eirini Tsermpini and Jacob T. Brown and Gillian Casey Bell and James Steven Leeder and Andrea Gaedigk and Stuart Alexander Scott and Teri E. Klein and Kelly E. Caudle and Jeffrey R. Bishop},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2023},
volume = {114},
number = {1},
pages = {51--68},
doi = {10.1002/cpt.2903},
url = {https://doi.org/10.1002/cpt.2903}
}TY - JOUR AU - Bousman, Chad AU - Stevenson, James Michael AU - Ramsey, Laura B. AU - Sangkuhl, Katrin AU - Hicks, James Kevin AU - Strawn, Jeffrey Robert AU - Singh, Ajeet AU - Ruaño, Gualberto AU - Müller, Daniel J. AU - Tsermpini, Evangelia Eirini AU - Brown, Jacob T. AU - Bell, Gillian Casey AU - Leeder, James Steven AU - Gaedigk, Andrea AU - Scott, Stuart Alexander AU - Klein, Teri E. AU - Caudle, Kelly E. AU - Bishop, Jeffrey R. TI - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants JO - Clinical Pharmacology & Therapeutics VL - 114 IS - 1 SP - 51 EP - 68 PY - 2023 DA - 2023/04/09 DO - 10.1002/cpt.2903 UR - https://doi.org/10.1002/cpt.2903 ER -
Add Find Research to Claude or ChatGPT and ask in plain language. The assistant reads this record, finds the papers around it and cites only what it actually found:
Setup takes about a minute: add the connector, then start the free trial.
Record from OpenAlex; open-access location from Unpaywall and the indexes. Find Research links only to legal copies.